A Randomized, Double-blind, Placebo-controlled Phase II Study of Pazopanib Versus Placebo as Maintenance Therapy for Patients Who Have Not Progressed After First-line Chemotherapy for Advanced Soft Tissue Sarcoma (STS)

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase II Study of Pazopanib Versus Placebo as Maintenance Therapy for Patients Who Have Not Progressed After First-line Chemotherapy for Advanced Soft Tissue Sarcoma (STS)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Oct 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 24 Feb 2015 Planned initiation date changed from 1 Apr 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov
    • 24 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top